Risankizumab outperforms ustekinumab in treating moderate-to-severe Crohn’s disease

Researchers compare the therapeutic efficacy of risakizumab and ustekinumab for the treatment of moderate-to-severe Crohn’s disease.

Breakthrough research identifies fibrin as key factor in preterm brain bleeds

Mark Petersen, MD, has seen firsthand the devastating effects of brain bleeds in premature babies. It’s an exceedingly common condition that affects up to 20

July 24, 2024

JPM dispatches: Nvidia, Recursion, Dexcom and more

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in

January 14, 2025

Combined vaccination and behavior change efforts averted 64% of US mpox cases, study reveals

The effectiveness of the combination of current preventive responses against monkeypox (Mpox).

January 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.